EMA To Beef Up Use Of PBPK Models In Drug Development And Evaluation
Executive Summary
New EU guideline will describe how drug developers should go about using physiologically-based pharmacokinetic (PBPK) modeling tools to help predict drug interactions, establish dosing in pediatric or Phase I trials, and other regulatory functions.